Skip to content

proteomic evaluation of Chikungunya

Quantitative proteomic evaluation of Chikungunya antibody positive participants compared to age and sex matched healthy controls in a tertiary care hospital of Western India

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/03/018051
Enrollment
140
Registered
2019-03-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A920- Chikungunya virus disease

Interventions

None listed

Sponsors

Research Society
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Able and willing to complete informed consent process with understanding of the purpose and procedures of the study Medical history and physical examination without clinically significant findings at the time of screening

Exclusion criteria

Exclusion criteria: Pregnant and lactating women History of active viral infection History of immune deficiency or autoimmune disease Have active or history of arthritis within the last 6 months from date of screening Have an active or history of malignant conditions including haematological malignancy Have a history of degenerative neurological disease Have received any vaccination within 4 weeks prior to this study Participants from the vaccine study who have received the Chikungunya vaccine Have received blood transfusion or immunoglobulin within 30 days prior to vaccination in this study

Design outcomes

Primary

MeasureTime frame
Based on the Plasma Proteome Database the end point of the present study is to identify at least 500 proteins among which 50 proteins are expected to be differentially expressed These differentially expressed proteins may help to discover newer vaccine for chikungunya infection in near future Proteomic analysis of plasma protein will also identify surrogate marker for diagnosis and prognosisTimepoint: September 2019

Secondary

MeasureTime frame
Based on the Plasma Proteome Database the end point of the present study is to identify at least 500 proteins among which 50 proteins are expected to be differentially expressed These differentially expressed proteins may help to discover newer vaccine for chikungunya infection in near future Proteomic analysis of plasma protein will also identify surrogate marker for diagnosis and prognosisTimepoint: 12 months

Countries

India

Contacts

Public ContactDebdipta Bose

Professor Seth GS Medical College and KEM Hospital Parel Mumbai 400012

njgogtay@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026